Status:
COMPLETED
Extension in AS: Sustainability of Benefits, Safety and Tolerability
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Spondylitis, Ankylosing
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, d...
Eligibility Criteria
Inclusion
- patients having completed the "core study" CAIN457F2305, indication for treatment extension. --
Exclusion
- history of hypersensitivity to secukinumab or to any drug of similar chemical classes, use of any investigational drug other than secukinumab during the "core study" CAIN457F2305.
Key Trial Info
Start Date :
November 6 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 16 2018
Estimated Enrollment :
274 Patients enrolled
Trial Details
Trial ID
NCT01863732
Start Date
November 6 2013
End Date
March 16 2018
Last Update
July 30 2019
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Portland, Oregon, United States, 97239
2
Novartis Investigative Site
Duncansville, Pennsylvania, United States, 16635
3
Novartis Investigative Site
Jackson, Tennessee, United States, 38305
4
Novartis Investigative Site
Kingsport, Tennessee, United States, 37660